The impact of vaccination on the breadth and magnitude of the antibody response to influenza a viruses in HIV-infected individuals

AIDS

Volumn 29, Issue 14, 2015, Pages 1803-1810

  Kohler, Ines ^a,c   Kouyos, Roger ^a,b   Bianchi, Matteo ^a   Grube, Christina ^b   Wyrzucki, Arkadiusz ^a,c   Günthard, Huldrych F ^a,b   Hangartner, Lars ^a,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Life Science Zurich   (Switzerland)

Author keywords

Antibodies; CD4+ T cells; Heterosubtypic; HIV; Influenza; Vaccination

Indexed keywords

HUMORAL ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H7N7); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS STRAIN; ADULT; ANTIBODY PRODUCTION; BLOOD; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SERODIAGNOSIS;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, HETEROLOGOUS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS;

EID: 84975137953     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000772     Document Type: Article

References (20)

1. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis 2011;52:219-227.
2. Francis T Jr. On the doctrine of original antigenic sin. Proc Am Philos Soc 1960;104:572-578.
3. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011;208:181-193.
4. Hu W, Chen A, Miao Y, Xia S, Ling Z, Xu K, et al. Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient. Virology 2013;435:320-328.
5. Kohler I, Scherrer AU, Zagordi O, Bianchi M, Wyrzucki A, Steck M, et al. Prevalence and predictors for homo- and heterosubtypic antibodies against influenza A virus. Clin Infect Dis 2014;59:1386-1393.
6. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006;6:138.
7. Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011;6:e17758.
8. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:206-211.
9. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008;122:12-19 quiz 20-11.
10. De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001;15:957-964.
11. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010;116:5571-5579.
12. Swiss HIVCS, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010;39:1179-1189.
13. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, Von Wyl V, Leemann C, et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013;208:1102-1112.
14. Rieder P, Joos B, Scherrer AU, Kuster H, Braun D, Grube C, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis 2011;53:1271-1279.
15. Kouyos RD, Von Wyl V, Yerly S, Boni J, Rieder P, Joos B, et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011;52:532-539.
16. Taffe P, May M, Swiss HIVCS. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008;27:4835-4853.
17. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328:357-360.
18. Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005;191:1442-1450.
19. Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008;197:572-579.
20. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998;12:F217-223.